Published in Clin Cancer Res on March 01, 2007
DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer (2008) 1.55
Deficiency in PER proteins has no effect on the rate of spontaneous and radiation-induced carcinogenesis. Cell Cycle (2013) 1.49
Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One (2010) 1.45
A role for the clock gene per1 in prostate cancer. Cancer Res (2009) 1.35
Disruption of the circadian clock due to the Clock mutation has discrete effects on aging and carcinogenesis. Cell Cycle (2008) 1.35
The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci (2013) 1.28
Age-related changes in mesenchymal stem cells derived from rhesus macaque bone marrow. Aging Cell (2011) 1.24
Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev (2010) 1.10
Circadian-independent cell mitosis in immortalized fibroblasts. Proc Natl Acad Sci U S A (2010) 1.09
Circadian rhythm connections to oxidative stress: implications for human health. Antioxid Redox Signal (2013) 1.00
Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res (2010) 0.97
Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One (2009) 0.96
Circadian rhythm and its role in malignancy. J Circadian Rhythms (2010) 0.94
Disruption of CLOCK-BMAL1 transcriptional activity is responsible for aryl hydrocarbon receptor-mediated regulation of Period1 gene. Toxicol Sci (2010) 0.94
Modulation of ATR-mediated DNA damage checkpoint response by cryptochrome 1. Nucleic Acids Res (2014) 0.85
Stress-induced changes in the expression of the clock protein PERIOD1 in the rat limbic forebrain and hypothalamus: role of stress type, time of day, and predictability. PLoS One (2014) 0.82
miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth. J Hepatol (2016) 0.81
The circadian control of skin and cutaneous photodamage. Photochem Photobiol (2012) 0.81
Circadian gene variants in cancer. Ann Med (2014) 0.81
Aberrant expression of Per1, Per2 and Per3 and their prognostic relevance in non-small cell lung cancer. Int J Clin Exp Pathol (2014) 0.81
Hidden treasures in "ancient" microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue. Front Oncol (2014) 0.81
Circadian genes Per1 and Per2 increase radiosensitivity of glioma in vivo. Oncotarget (2015) 0.80
The clock gene PER1 suppresses expression of tumor-related genes in human oral squamous cell carcinoma. Oncotarget (2016) 0.80
Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma. Leuk Lymphoma (2012) 0.80
Varied pathways of stage IA lung adenocarcinomas discovered by integrated gene expression analysis. Int J Biol Sci (2011) 0.79
Impaired light detection of the circadian clock in a zebrafish melanoma model. Cell Cycle (2015) 0.78
Year-in-Review of Lung Cancer. Tuberc Respir Dis (Seoul) (2012) 0.77
Glucocorticoids and Stress-Induced Changes in the Expression of PERIOD1 in the Rat Forebrain. PLoS One (2015) 0.77
Role of Epigenetics in Biology and Human Diseases. Iran Biomed J (2016) 0.75
Case-control study of candidate gene methylation and adenomatous polyp formation. Int J Colorectal Dis (2016) 0.75
Circadian gene expression predicts patient response to neoadjuvant chemoradiation therapy for rectal cancer. Int J Clin Exp Pathol (2015) 0.75
Carcinogenic effects of circadian disruption: an epigenetic viewpoint. Chin J Cancer (2015) 0.75
Epigenetic regulation of the circadian clock: role of 5-aza-2'-deoxycytidine. Biosci Rep (2017) 0.75
Period 1 and estrogen receptor-beta are downregulated in Chinese colon cancers. Int J Clin Exp Pathol (2015) 0.75
Expression of circadian clock genes and proteins in urothelial cancer is related to cancer-associated genes. BMC Cancer (2016) 0.75
Evolving roles of circadian rhythms in liver homeostasis and pathology. Oncotarget (2016) 0.75
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J (2005) 4.36
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell (2006) 2.71
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis (2009) 2.34
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet (2013) 2.14
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene (2005) 2.06
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood (2002) 2.03
Differentiation therapy of leukemia: 3 decades of development. Blood (2009) 2.02
Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood (2004) 1.99
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci U S A (2002) 1.92
Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res (2004) 1.85
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood (2012) 1.85
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res (2006) 1.82
Optically active single-walled carbon nanotubes. Nat Nanotechnol (2007) 1.81
Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One (2007) 1.79
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med (2013) 1.79
Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res (2006) 1.74
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer (2007) 1.72
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood (2010) 1.70
Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res (2004) 1.68
In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. Int J Cancer (2007) 1.64
C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res (2002) 1.64
Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation. Mol Cell (2013) 1.62
Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood (2002) 1.60
A system for sharing routine surgical pathology specimens across institutions: the Shared Pathology Informatics Network. Hum Pathol (2007) 1.59
BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med (2010) 1.56
Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leuk Res (2005) 1.56
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem (2007) 1.53
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res (2007) 1.53
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res (2004) 1.50
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood (2003) 1.50
Miliary tuberculosis not affecting the lungs but complicated by acute respiratory distress syndrome. Intern Med (2005) 1.46
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol (2005) 1.45
Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res (2006) 1.45
The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol (2004) 1.43
Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res (2009) 1.43
Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood (2003) 1.40
Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene (2002) 1.37
Myelodysplastic syndrome. Annu Rev Med (2005) 1.37
A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther (2007) 1.36
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood (2007) 1.36
Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. Int Immunopharmacol (2011) 1.35
A role for the clock gene per1 in prostate cancer. Cancer Res (2009) 1.35
Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood (2005) 1.35
Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci U S A (2008) 1.34
Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res (2006) 1.33
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res (2006) 1.32
Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP epsilon and PU.1. Blood (2002) 1.32
Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem (2003) 1.31
Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood (2008) 1.30
HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci (2005) 1.28
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci (2004) 1.28
Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway. J Biol Chem (2003) 1.27
FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer (2007) 1.25
Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem (2004) 1.25
Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer (2004) 1.25
Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther (2005) 1.23
Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem (2003) 1.23
Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates. BMC Genomics (2009) 1.22
Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer (2002) 1.21
The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther (2006) 1.20